secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-05-27T12:10:30+00:00
Accession:  0001213900-26-061244
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics announces peer-reviewed publication supporting GX-03's activity in IL-36 inflammatory model
--------------------------------------------------------------------------------

- Study in murine dermatitis model showed mean IGA score of 1.44 vs 3.00 for untreated controls (p=0.0003) after 7 days of GX-03.
- No treatment-related adverse effects observed; IL-36 expression confirmed following Staphylococcus aureus exposure.
- Publication in Journal of Dermatological Treatment; first in planned series on GX-03's scientific rationale.
- GX-03 is in Phase 2 for moderate-to-severe atopic dermatitis; topline results expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026061244/0001213900-26-061244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026061244/ea0291866-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-061244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer